Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precigen, Inc. on May 24, 2021. The Company is a clinical-stage biopharmaceutical organization currently conducting an executive search for a permanent Chief Financial Officer to support its transition to a commercial organization.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure of Principal Officer: D. Bradford Osborne resigned as Vice President, Finance and Accounting, and interim principal accounting officer. His resignation is effective June 10, 2021.
- Appointment of Interim Officer: James V. Lambert, currently Executive Director, Finance for PGEN Therapeutics, Inc. (a wholly owned subsidiary), was appointed as the interim principal accounting officer effective June 10, 2021.
Outlook, Risks, and Management Commentary
Management confirmed that the Company continues its search for a new Chief Financial Officer. Mr. Lambert will serve in an interim capacity during this process. There are no changes to Mr. Lambert's compensation arrangements, and no undisclosed arrangements or material interests were identified regarding his selection.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a permanent Chief Financial Officer.
- Confirm the effective date of the leadership transition (June 10, 2021).
- Review the background of James V. Lambert, noting his prior roles at GenVec, Inc. and PGEN Therapeutics since 2014.
- Monitor future filings for the conclusion of the executive search process.